Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) will present a live video webcast as part of the Webull Financial Corporate Connect Webinar Series on Wednesday, February 11, 2026 at 1:20 PM EST. Walter Klemp, Founder, President, CEO and Chairman, is the scheduled presenter. Registration is available via the company's provided link.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MBRX declined 6.46%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $774K from the company's valuation, bringing the market cap to $11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows only peer MBIO notably active, down 16.619999706745148% without news. No evidence of a coordinated move across multiple biotechnology peers around this communication-focused update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Operational expansion | Neutral | +3.1% | Third-party logistics deal to establish U.S. fulfillment hub in Missouri. |
| Jan 13 | Safety update | Positive | +5.9% | Independent assessment found no cardiotoxicity for Annamycin in 90 subjects. |
| Jan 12 | Pipeline outlook | Positive | +1.8% | Outlined 2026–2028 milestones and MIRACLE trial expansion and unblinding plans. |
| Dec 17 | Clinical trial data | Positive | -11.7% | Positive Phase 1 WP1066 data in pediatric brain tumors, including partial response. |
| Dec 10 | Warrant exercise | Negative | -27.1% | Warrant exercises and issuance of new warrants for additional common shares. |
News often aligns with price moves: positive clinical and financing updates typically saw matching moves, though one positive trial result drew a sharp negative reaction.
Over the past few months, Moleculin has highlighted several clinical and corporate developments. On Dec 10, 2025, a warrant exercise for roughly $6.5 million gross proceeds coincided with a -27.15% move, suggesting sensitivity to dilution. Positive Phase 1 WP1066 data on Dec 17, 2025 saw a -11.73% reaction, while January 2026 updates on MIRACLE trial progress and Annamycin cardiotoxicity in 90 subjects produced modest gains. Today’s webinar appearance fits a pattern of ongoing investor outreach alongside advancing programs.
Regulatory & Risk Context
The company has an active S-3 shelf registration dated 2025-09-19 that remains effective through 2028-09-19, with no recorded usage to date in the provided context. Specific dollar capacity was not disclosed here.
Market Pulse Summary
The stock moved -6.5% in the session following this news. A negative reaction despite this routine webinar disclosure would fit a backdrop where the stock has occasionally sold off even on positive developments, such as the -11.73% move after favorable Phase 1 WP1066 data. With the current price at $4.18, well under the $12.79 200-day MA and $91.2475 52-week high, weakness could reflect broader skepticism toward small-cap biotech communications rather than this specific event.
Key Terms
webinar technical
AI-generated analysis. Not financial advice.
– Live video webcast on Wednesday, February 11th at 1:20 PM EST
HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.
Details of the presentation are as follows:
Date and Time: Wednesday, February 11, 2026 at 1:20 PM EST
Presenter: Walter Klemp, Founder, President, CEO and Chairman of Moleculin
Registration Link: Here
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
FAQ
When will Moleculin (MBRX) present at the Webull Corporate Connect Webinar Series?
Who is presenting for Moleculin (MBRX) at the February 2026 Webull webinar?
How can investors register for Moleculin's (MBRX) Webull webinar presentation?
What format will Moleculin's (MBRX) presentation take at the Webull event?
Will Moleculin (MBRX) present any financial or clinical updates at the Webull webinar?
